How should I write an IV iron order for ferric carboxymaltose (Injectafer) in a patient with a serum ferritin of 15.4 ng/mL?

Injectafer Order for Ferritin 15.4 ng/mL

For a patient weighing ≥50 kg with iron deficiency anemia (ferritin 15.4 ng/mL), order Injectafer 750 mg IV infused over 15 minutes, to be repeated once after at least 7 days for a total cumulative dose of 1,500 mg. 1

Dosing Algorithm Based on Patient Weight

Patients ≥50 kg

• Standard regimen: Injectafer 750 mg IV × 2 doses separated by at least 7 days (total 1,500 mg per course) 1
• Alternative single-dose regimen: Injectafer 15 mg/kg (maximum 1,000 mg) IV as a single dose per course 1
• The two-dose 750 mg regimen is preferred because it delivers the full 1,500 mg repletion dose that has been validated in clinical trials 2, 3

Patients <50 kg

• Dose: Injectafer 15 mg/kg IV × 2 doses separated by at least 7 days 1

Administration Instructions for the Order

Write the order as follows:

• Medication: Injectafer (ferric carboxymaltose) 750 mg IV
• Preparation: Dilute 750 mg (15 mL from vial) in 250 mL normal saline (concentration ≥2 mg iron/mL) 1
• Rate: Infuse over 15 minutes 1
• Alternative: May give undiluted as slow IV push at approximately 100 mg (2 mL) per minute 1
• Monitoring: Observe patient for hypersensitivity reactions during infusion and for at least 30 minutes after completion 1
• Repeat dose: Schedule second dose of 750 mg IV at least 7 days after first dose 1

Pre-Administration Safety Checks

• Contraindications: Confirm no prior hypersensitivity to Injectafer or its components 1
• Baseline phosphate: Check serum phosphate in patients at risk for hypophosphatemia (inflammatory bowel disease, malabsorption disorders, prior bariatric surgery, vitamin D deficiency, hyperparathyroidism) 1
• Emergency preparedness: Ensure personnel and equipment for anaphylaxis management are immediately available 1

Monitoring After Administration

Immediate Post-Infusion (0–30 minutes)

• Monitor vital signs and observe for hypersensitivity reactions (hypotension, flushing, dizziness, nausea, rash, wheezing) until clinically stable 1
• Transient blood pressure elevations with facial flushing occur in 6% of patients and typically resolve within 30 minutes 1

Short-Term Follow-Up (1–2 weeks)

• Hemoglobin typically begins rising within 1–2 weeks after IV iron 4

Optimal Reassessment Window (4–8 weeks)

• Do not measure ferritin or transferrin saturation within the first 4 weeks because values are falsely elevated immediately after IV iron 4, 5
• Recheck CBC and iron studies at 4–8 weeks post-infusion to assess response 4, 5
• Expected hemoglobin rise: 1–2 g/dL by 4–8 weeks 4
• Target ferritin: ≥100 ng/mL (higher threshold than oral iron due to inflammatory effects) 5
• Target transferrin saturation: ≥20% 5

Long-Term Surveillance

• Monitor CBC every 3 months for the first year after iron repletion 4, 5
• After the first year, monitor every 6 months for the next 2–3 years to detect recurrence 4

Criteria for Repeat Treatment

• Repeat course indications: Recurrent iron deficiency anemia (hemoglobin decline, ferritin <100 ng/mL, or transferrin saturation <20%) 1
• Safety requirement: Check serum phosphate before any repeat course, especially if repeat dosing occurs within 3 months 1
• Symptomatic hypophosphatemia requiring clinical intervention has been reported after repeated Injectafer exposure 1

Common Pitfalls to Avoid

• Measuring ferritin too early: Ferritin rises markedly after IV iron and cannot be used as a reliable marker within 4 weeks of administration 4, 5
• Inadequate observation period: Serious hypersensitivity reactions can occur; the 30-minute post-infusion monitoring period is mandatory 1
• Ignoring phosphate monitoring: Patients with malabsorption, IBD, or those receiving repeat courses within 3 months require phosphate monitoring 1
• Extravasation: Monitor IV site closely; brown discoloration from extravasation may be long-lasting 1
• Premature discontinuation of monitoring: Failure to continue surveillance allows recurrence of iron deficiency and may mask underlying pathology such as occult bleeding 4, 5

Expected Clinical Response

• Hemoglobin improvement: 60% of patients achieve ≥1 g/dL rise in hemoglobin with IV ferric carboxymaltose versus 35% with oral iron 2
• Iron store repletion: Mean ferritin increase of approximately 400 ng/mL by 6 weeks 2
• Transferrin saturation: Mean increase of 13–14% by 6 weeks 2
• Tolerability: Treatment-related adverse events occur in only 2.7% of patients receiving IV ferric carboxymaltose versus 26% with oral iron 2